Last $21.20 USD
Change Today +0.22 / 1.05%
Volume 23.8K
TKPYY On Other Exchanges
Symbol
Exchange
Tokyo
OTC US
OTC US
Frankfurt
As of 8:10 PM 10/24/14 All times are local (Market data is delayed by at least 15 minutes).

takeda pharmaceutic-sp adr (TKPYY) Snapshot

Open
$21.01
Previous Close
$20.98
Day High
$21.20
Day Low
$21.01
52 Week High
12/11/13 - $25.09
52 Week Low
10/17/14 - $20.47
Market Cap
33.5B
Average Volume 10 Days
86.4K
EPS TTM
--
Shares Outstanding
1.6B
EX-Date
09/25/14
P/E TM
--
Dividend
$0.89
Dividend Yield
2.09%
Current Stock Chart for TAKEDA PHARMACEUTIC-SP ADR (TKPYY)

Related News

No related news articles were found.

takeda pharmaceutic-sp adr (TKPYY) Details

Takeda Pharmaceutical Company Limited is engaged in the research, development, manufacturing, marketing, sale, and import/export of pharmaceutical drugs worldwide. It provides products in various therapeutic areas, including cardiovascular and metabolic, respiratory and immunology, oncology, central nervous system, general medicine, vaccines, and consumer healthcare drugs and quasi-drugs. The company has strategic partnership with BioMotiv, LLC. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Osaka, Japan.

31,225 Employees
Last Reported Date: 06/27/14
Founded in 1781

takeda pharmaceutic-sp adr (TKPYY) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

takeda pharmaceutic-sp adr (TKPYY) Key Developments

Sucampo Pharmaceuticals, Inc. Announces Extension of AMITIZA(R) (lubiprostone) License and Collaboration Agreement with Takeda Pharmaceutical Company Ltd

Sucampo Pharmaceuticals, Inc. announced that it signed on October 9, 2014 an amendment to the existing collaboration and license agreement (Collaboration Agreement) covering the United States (U.S.) and Canada for AMITIZA(R) (lubiprostone) with Takeda Pharmaceutical Company Ltd. (Takeda). The amendment includes various modifications to the Collaboration Agreement including the extension of the current term, minimum commercial investment during the current term and various governance changes allowing Takeda additional flexibility in commercializing AMITIZA. During the extended term, which will begin on January 1, 2021, Takeda will split with Sucampo the gross profits of branded AMITIZA for any dosage strength and form for the existing indications in the U.S. and Canada. In addition, on April 1, 2015 Takeda will no longer reimburse Sucampo for the product details made by Sucampo sales representatives to healthcare professionals as well as other ancillary costs of the sales force.

Sucampo Pharmaceuticals, Inc., Sucampo AG, R-Tech Ueno, Ltd. and Takeda Pharmaceutical Company Limited Enters into Settlement and License Agreement with Anchen Pharmaceuticals, Inc., Par Pharmaceutical, Inc. and Par Pharmaceutical Companies, Inc

Sucampo Pharmaceuticals, Inc. announced that it, its affiliate Sucampo AG, R-Tech Ueno, Ltd., Takeda Pharmaceutical Company Limited and certain affiliates of Takeda have entered into a settlement and license agreement with Anchen Pharmaceuticals, Inc., Par Pharmaceutical, Inc. and Par Pharmaceutical Companies, Inc. that resolves patent litigation in the United States (U.S.) related to Sucampo's AMITIZA(R) (lubiprostone) 8 mcg soft gelatin capsule and 24 mcg soft gelatin capsule. Under the terms of the settlement, Sucampo and RTU will grant Par a non-exclusive license to market Par's generic version of lubiprostone 8 mcg soft gelatin capsule and 24 mcg soft gelatin capsule (licensed products) in the U.S. for the indications approved for AMITIZA(R) beginning January 1, 2021, or earlier under certain circumstances. Beginning on January 1, 2021, Par will split with Sucampo the gross profits of the licensed products sold during the term of the agreement, which continues until each of the Sucampo patents has expired. In the event Par elects to launch an authorized generic, Sucampo will supply Par under the terms of a manufacturing and supply agreement at a negotiated price. Additional details of the agreement remain confidential. Additionally, Sucampo, RTU, Takeda, and Par have agreed to dismiss with prejudice the patent litigation filed in the United States District Court for the District of Delaware.

FDA Approves Velcade for Injection for Previously Untreated Patients with Mantle Cell Lymphoma

Takeda Pharmaceutical Company Limited announced that the U.S. Food and Drug Administration has approved VELCADE (bortezomib) for injection for use in previously untreated patients with mantle cell lymphoma (MCL). VELCADE is the first treatment in the United States to be approved for use in previously untreated patients with MCL. This approval extends the utility of VELCADE beyond relapsed or refractory mantle cell lymphoma, for which it has been approved since 2006. This approval is based on the results of an international, randomized, head-to-head Phase 3 study that showed that previously untreated patients receiving a VELCADE-containing combination (VcR-CAP) experienced a 59% relative improvement in the study's primary endpoint of progression-free survival (PFS) compared to those who were administered the standard R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) regimen (median 25 vs. 14 months; Hazard Ratio 0.63; P<0.001) at a median follow up of 40 months. An Independent Review Committee (IRC) assessed the primary efficacy endpoint of PFS. The complete response (CR) rate for patients receiving VcR-CAP vs. R-CHOP was 44% vs. 34%. The open-label, multicenter, prospective study evaluated the efficacy and safety of VcR-CAP vs. R-CHOP in 487 patients with previously untreated MCL who were ineligible or not considered for a bone marrow transplant. VELCADE (1.3 mg/m(2)) is administered intravenously in combination with intravenous rituximab, cyclophosphamide, doxorubicin and oral prednisone (VcR-CAP) for six 3-week treatment cycles. VELCADE is administered first followed by rituximab. VELCADE is administered twice weekly for two weeks (days 1, 4, 8 and 11) followed by a 10-day rest period on days 12-21. For patients with a response first documented at cycle 6, two additional VcR-CAP cycles are recommended. At least 72 hours should elapse between consecutive doses of VELCADE. The most common adverse reactions occurring in >=20% of patients receiving the VcR-CAP regimen were neutropenia, leukopenia, anemia, thrombocytopenia, lymphopenia, peripheral neuropathy, pyrexia, nausea and diarrhea. Infections were reported for 31% of patients in the VcR-CAP arm and 23% of the patients in the R-CHOP arm including pneumonia (8% versus 5%). Adverse reactions leading to discontinuation occurred in 8% of patients in the VcR-CAP arm and 6% of patients in the R-CHOP arm. In the VcR-CAP group, the most commonly reported adverse reaction leading to discontinuation was peripheral sensory neuropathy (1%; 3 patients).

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TKPYY:US $21.20 USD +0.22

TKPYY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $42.46 USD +0.03
Astellas Pharma Inc ¥1,598 JPY +20.50
Baxter International Inc $69.83 USD +0.73
Becton Dickinson and Co $125.73 USD +0.73
Shire PLC 4,050 GBp +155.00
View Industry Companies
 

Industry Analysis

TKPYY

Industry Average

Valuation TKPYY Industry Range
Price/Earnings 30.3x
Price/Sales 2.0x
Price/Book 1.4x
Price/Cash Flow 11.8x
TEV/Sales 1.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TAKEDA PHARMACEUTIC-SP ADR, please visit www.takeda.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.